Matthew Carlson
Research Subjects
Matthew Carlson has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- David Scott Miller
University of Texas Southwestern Medical Center, Dallas, TX
4 shared publications - Jayanthi S. Lea
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
4 shared publications Debra L. Richardson
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology
2 shared publicationsDustin B. Manders
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology
2 shared publicationsSiobhan M. Kehoe
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology
2 shared publications- Alaine F. Camfield
Environm & Climate Change Canada, Canadian Wildlife Serv, Gatineau, PQ, Canada
1 shared publication
Latest Publications
- Open Access
- 6 August 2021
- Published by Wiley in The Journal of Wildlife Management
- Vol. 85 (7) , 1355-1376
Modeling Cumulative Effects of Climate and Development on Moose, Wolf, and Caribou Populations
Wildlife models focused solely on a single strong influence (e.g., habitat components, wildlife harvest) are limited in their ability to detect key mechanisms influencing population change. Instead, we propose integrated modeling in the context of cumulative effects assessment using multispecies population dynamics models linked to landscape‐climate simulation at large spatial and temporal scales. We developed an integrated landscape and population simulation model using ALCES Online as the model‐building platform, and the model accounted for key ecological components and relationships among moose (Alces alces), grey wolves (Canis lupus nubilus), and woodland caribou (Rangifer tarandus caribou) in northern Ontario, Canada. We simulated multiple scenarios over 5 decades (beginning 2020) to explore sensitivity to climate change and land use and assessed effects at multiple scales. The magnitude of effect and the relative importance of key factors (climate change, roads, and habitat) differed depending on the scale of assessment. Across the full extent of the study area (654,311km2[ecozonal scale]), the caribou population declined by 26% largely because of climate change and associated predator‐prey response, which led to caribou range recession in the southern part of the study area. At the caribou range scale (108,378 km2), which focused on 2 herds in the northern part of the study area, climate change led to a 10% decline in the population and development led to an additional 7% decline. At the project scale (8,331 km2), which was focused more narrowly on the landscape surrounding 4 proposed mines, the caribou population declined by 29% largely in response to simulated development. Given that observed caribou population dynamics were sensitive to the cumulative effects of climate change, land use, interspecific interactions, and scale, insights from the analysis might not emerge under a less complex model. Our integrated modeling framework provides valuable support for broader regional assessments, including estimation of risk to caribou and Indigenous food security, and for developing and evaluating potential caribou recovery strategies. © 2021 The Authors.The Journal of Wildlife Managementpublished by Wiley Periodicals LLC on behalf of The Wildlife Society.
- 6 August 2021
- Published by Wiley in The Journal of Wildlife Management
- Vol. 85 (7) , 1355-1376
Open AccessModeling Cumulative Effects of Climate and Development on Moose, Wolf, and Caribou Populations
Wildlife models focused solely on a single strong influence (e.g., habitat components, wildlife harvest) are limited in their ability to detect key mechanisms influencing population change. Instead, we propose integrated modeling in the context of cumulative effects assessment using multispecies population dynamics models linked to landscape‐climate simulation at large spatial and temporal scales. We developed an integrated landscape and population simulation model using ALCES Online as the model‐building platform, and the model accounted for key ecological components and relationships among moose (Alces alces), grey wolves (Canis lupus nubilus), and woodland caribou (Rangifer tarandus caribou) in northern Ontario, Canada. We simulated multiple scenarios over 5 decades (beginning 2020) to explore sensitivity to climate change and land use and assessed effects at multiple scales. The magnitude of effect and the relative importance of key factors (climate change, roads, and habitat) differed depending on the scale of assessment. Across the full extent of the study area (654,311km2[ecozonal scale]), the caribou population declined by 26% largely because of climate change and associated predator‐prey response, which led to caribou range recession in the southern part of the study area. At the caribou range scale (108,378 km2), which focused on 2 herds in the northern part of the study area, climate change led to a 10% decline in the population and development led to an additional 7% decline. At the project scale (8,331 km2), which was focused more narrowly on the landscape surrounding 4 proposed mines, the caribou population declined by 29% largely in response to simulated development. Given that observed caribou population dynamics were sensitive to the cumulative effects of climate change, land use, interspecific interactions, and scale, insights from the analysis might not emerge under a less complex model. Our integrated modeling framework provides valuable support for broader regional assessments, including estimation of risk to caribou and Indigenous food security, and for developing and evaluating potential caribou recovery strategies. © 2021 The Authors.The Journal of Wildlife Managementpublished by Wiley Periodicals LLC on behalf of The Wildlife Society.
- Open Access
- 1 November 2020
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 34, 100620
Current practice patterns in nodal evaluation and adjuvant treatment of advanced stage endometrioid endometrial cancer: An SGO survey
- 1 November 2020
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 34, 100620
Open AccessCurrent practice patterns in nodal evaluation and adjuvant treatment of advanced stage endometrioid endometrial cancer: An SGO survey
- 4 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 156 (1) , 100-106
Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy
- 4 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 156 (1) , 100-106
Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy
- 1 November 2018
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 41 (11) , 1137-1141
Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer
Objective: Cervical cancer presenting with metastases to the bony pelvis is rare. No available literature addresses the treatment and prognosis of these patients. Our objective was to review our experience treating women with this rare presentation. Methods: We performed a review of all patients treated for cervical cancer at a single institution between January 1, 2007 and November 30, 2014. All patients had pretreatment imaging with computed tomography or positron emission tomography/computed tomography. Included patients had evidence of pelvic bone metastases by imaging before initiation of treatment. Results: A total of 349 women were treated for cervical cancer during the study interval. Of these, 13 (3.7%) were identified as having pelvic bone metastases at initial presentation. Four of 13 patients had pelvic-confined disease and were treated with curative-intent radiation. The remainder had disseminated disease and were treated with palliative radiation. Only one complete response was seen. Seven patients received salvage chemotherapy. The median overall survival was 8.5 months. Survival was statistically similar in those who received palliative rather than curative radiotherapy (8.7 vs. 8.1 mo, P=0.76) and in those who received any postradiation chemotherapy (8.9 vs. 6.1 mo, P=0.066). Chemotherapy with bevacizumab resulted in the only 2 long-term survivors (both alive at 32.4 and 37.5 mo). All others have died of disease. Conclusions: Cervical cancer metastatic to the bony pelvis at initial presentation portends a dismal prognosis. Patients should be informed about this poor prognosis, and allowed to make an informed decision when considering curative-intent versus palliative treatment. Incorporation of bevacizumab appears to improve survival.
- 1 November 2018
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 41 (11) , 1137-1141
Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer
Objective: Cervical cancer presenting with metastases to the bony pelvis is rare. No available literature addresses the treatment and prognosis of these patients. Our objective was to review our experience treating women with this rare presentation. Methods: We performed a review of all patients treated for cervical cancer at a single institution between January 1, 2007 and November 30, 2014. All patients had pretreatment imaging with computed tomography or positron emission tomography/computed tomography. Included patients had evidence of pelvic bone metastases by imaging before initiation of treatment. Results: A total of 349 women were treated for cervical cancer during the study interval. Of these, 13 (3.7%) were identified as having pelvic bone metastases at initial presentation. Four of 13 patients had pelvic-confined disease and were treated with curative-intent radiation. The remainder had disseminated disease and were treated with palliative radiation. Only one complete response was seen. Seven patients received salvage chemotherapy. The median overall survival was 8.5 months. Survival was statistically similar in those who received palliative rather than curative radiotherapy (8.7 vs. 8.1 mo, P=0.76) and in those who received any postradiation chemotherapy (8.9 vs. 6.1 mo, P=0.066). Chemotherapy with bevacizumab resulted in the only 2 long-term survivors (both alive at 32.4 and 37.5 mo). All others have died of disease. Conclusions: Cervical cancer metastatic to the bony pelvis at initial presentation portends a dismal prognosis. Patients should be informed about this poor prognosis, and allowed to make an informed decision when considering curative-intent versus palliative treatment. Incorporation of bevacizumab appears to improve survival.
- 1 October 2018
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 41 (10) , 933-937
Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer
Objective: Antivascular endothelial growth factor monoclonal antibodies inhibit tumor angiogenesis, consequently impeding the recruitment of new vasculature to existing and new tumor lesions. We sought to evaluate toxicities in women with recurrent cervical cancer after receiving bevacizumab combination chemotherapy. Methods: A review was conducted of women with recurrent and metastatic cervical cancer who were treated with salvage chemotherapy with or without bevacizumab between 2005 and 2015. Clinicopathologic data and reasons for treatment discontinuation were recorded. Patients that were excluded had other histology than squamous or adenocarcinoma, received 1 cycle of salvage chemotherapy, single agent bevacizumab, currently on treatment, or noncompliant. Statistical analysis was performed using the Fishers Exact Test, logistic regression, and Kaplan-Meier Survival Analysis. Results: A total of 74 patients were included in analysis. Twenty-six patients were treated with bevacizumab (BEV) and chemotherapy and 48 patients with chemotherapy alone (chemotherapy). The progression free survival was significant with median 12 months versus 7 months for the BEV cohort (PP=0.06). Cessation of treatment secondary to severe toxicities was seen in 46% (n=12) of BEV cohort versus 15% (n=7) of chemotherapy cohort (PP=0.004 and 0.024, respectively). Conclusions: Hypoalbuminemia and bevacizumab treatments are significant predictive factors of fistula formation in patients treated for recurrent cervical cancer.
- 1 October 2018
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 41 (10) , 933-937
Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer
Objective: Antivascular endothelial growth factor monoclonal antibodies inhibit tumor angiogenesis, consequently impeding the recruitment of new vasculature to existing and new tumor lesions. We sought to evaluate toxicities in women with recurrent cervical cancer after receiving bevacizumab combination chemotherapy. Methods: A review was conducted of women with recurrent and metastatic cervical cancer who were treated with salvage chemotherapy with or without bevacizumab between 2005 and 2015. Clinicopathologic data and reasons for treatment discontinuation were recorded. Patients that were excluded had other histology than squamous or adenocarcinoma, received 1 cycle of salvage chemotherapy, single agent bevacizumab, currently on treatment, or noncompliant. Statistical analysis was performed using the Fishers Exact Test, logistic regression, and Kaplan-Meier Survival Analysis. Results: A total of 74 patients were included in analysis. Twenty-six patients were treated with bevacizumab (BEV) and chemotherapy and 48 patients with chemotherapy alone (chemotherapy). The progression free survival was significant with median 12 months versus 7 months for the BEV cohort (PP=0.06). Cessation of treatment secondary to severe toxicities was seen in 46% (n=12) of BEV cohort versus 15% (n=7) of chemotherapy cohort (PP=0.004 and 0.024, respectively). Conclusions: Hypoalbuminemia and bevacizumab treatments are significant predictive factors of fistula formation in patients treated for recurrent cervical cancer.
- Open Access
- 1 January 2018
- Published by Resilience Alliance, Inc. in Avian Conservation and Ecology
- Vol. 13 (2)
Strategies for identifying priority areas for songbird conservation in Canada’s boreal forest
Stralberg, D., A. Camfield, M. Carlson, C. Lauzon, A. Westwood, N. K. S. Barker, S. J. Song. and F. K. A. Schmiegelow. 2018. Strategies for identifying priority areas for songbird conservation in Canada’s boreal forest. Avian Conservation and Ecology 13(2):12. https://doi.org/10.5751/ACE-01303-130212
- 1 January 2018
- Published by Resilience Alliance, Inc. in Avian Conservation and Ecology
- Vol. 13 (2)
Open AccessStrategies for identifying priority areas for songbird conservation in Canada’s boreal forest
Stralberg, D., A. Camfield, M. Carlson, C. Lauzon, A. Westwood, N. K. S. Barker, S. J. Song. and F. K. A. Schmiegelow. 2018. Strategies for identifying priority areas for songbird conservation in Canada’s boreal forest. Avian Conservation and Ecology 13(2):12. https://doi.org/10.5751/ACE-01303-130212
- 1 March 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (3) , 586-591
The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment
- 1 March 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (3) , 586-591
The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment
- 21 November 2014
- Published by Springer Nature
- p. 219-244
Alberta Oil Sands Development and Risk Management of Canadian Boreal Ecosystems
- 21 November 2014
- Published by Springer Nature
- p. 219-244
Alberta Oil Sands Development and Risk Management of Canadian Boreal Ecosystems
- 1 February 2013
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 74 (S 01) , A132
Quality-of-Life Comparing Observation, Microsurgery, and Radiosurgery for Small- to Medium-Sized Vestibular Schwannoma Using a Validated Disease-Specific Instrument
Objectives: (1) To compare long-term quality-of-life (QOL) outcomes following “wait and scan” observation (WSO), microsurgery (MS), and stereotactic radiosurgery (SRS) for small-to-medium sized vestibular schwannoma (VS) using a newly validated disease-specific instrument; (2) to identify clinical variables associated with QOL outcome scores. Design: Cross-sectional study. Patients/Materials and Methods: Adult patients who underwent primary MS, WSO, or SRS for sporadic small-to-medium sized (≤2.0 cm) VS between 1998 and 2008 were surveyed using the Penn Acoustic Neuroma Quality-of-Life (PANQOL) Scale 1 and the Mayo Clinic VS symptom questionnaire (MCVSSQ). The PANQOL domain and total scores and MCVSSQ responses for the three groups of interest were compared using the Kruskal-Wallis test for continuous or ordinal variables and chi-square or Fisher exact test for categorical variables. Associations between responses to the MCVSSQ and total PANQOL scores among all patients were interrogated using multivariable regression. Results: The first 40 consecutive respondents from each group were analyzed (N = 120). The mean duration between date of treatment and time of survey was 8.2 years. Subjects managed with MS were significantly younger (P < 0.000) than those receiving WSO or SRS, and tumors followed with WSO were significantly smaller than those treated with SRS (P = 0.007). Results showed that 95% of WSO and SRS subjects and 85% of MS patients were satisfied with their overall outcome (P = 0.21). Patients managed with WSO were more likely to report useful ipsilateral hearing and normal facial motor function compared with those undergoing active treatment. There was a trend toward more frequent (P = 0.07) and severe (P = 0.1) headaches within the MS group. The frequency and perceived severity of dizziness was similar between groups. There were no statistical differences between the three study groups when investigating individual domain or total PANQOL scores (P = 0.51). When collectively analyzing all subjects, multivariable regression analysis demonstrated that headache (P < 0.000) and dizziness (P < 0.000) were most strongly associated with total QOL scores. Conclusions: Based on these data, patients with small-to-medium sized VS enjoy comparable long-term QOL and report high outcome satisfaction whether managed with WSO, MS, or SRS. Strategies addressing dizziness and headache may provide the most impact on QOL improvement for patients with VS.
- 1 February 2013
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 74 (S 01) , A132
Quality-of-Life Comparing Observation, Microsurgery, and Radiosurgery for Small- to Medium-Sized Vestibular Schwannoma Using a Validated Disease-Specific Instrument
Objectives: (1) To compare long-term quality-of-life (QOL) outcomes following “wait and scan” observation (WSO), microsurgery (MS), and stereotactic radiosurgery (SRS) for small-to-medium sized vestibular schwannoma (VS) using a newly validated disease-specific instrument; (2) to identify clinical variables associated with QOL outcome scores. Design: Cross-sectional study. Patients/Materials and Methods: Adult patients who underwent primary MS, WSO, or SRS for sporadic small-to-medium sized (≤2.0 cm) VS between 1998 and 2008 were surveyed using the Penn Acoustic Neuroma Quality-of-Life (PANQOL) Scale 1 and the Mayo Clinic VS symptom questionnaire (MCVSSQ). The PANQOL domain and total scores and MCVSSQ responses for the three groups of interest were compared using the Kruskal-Wallis test for continuous or ordinal variables and chi-square or Fisher exact test for categorical variables. Associations between responses to the MCVSSQ and total PANQOL scores among all patients were interrogated using multivariable regression. Results: The first 40 consecutive respondents from each group were analyzed (N = 120). The mean duration between date of treatment and time of survey was 8.2 years. Subjects managed with MS were significantly younger (P < 0.000) than those receiving WSO or SRS, and tumors followed with WSO were significantly smaller than those treated with SRS (P = 0.007). Results showed that 95% of WSO and SRS subjects and 85% of MS patients were satisfied with their overall outcome (P = 0.21). Patients managed with WSO were more likely to report useful ipsilateral hearing and normal facial motor function compared with those undergoing active treatment. There was a trend toward more frequent (P = 0.07) and severe (P = 0.1) headaches within the MS group. The frequency and perceived severity of dizziness was similar between groups. There were no statistical differences between the three study groups when investigating individual domain or total PANQOL scores (P = 0.51). When collectively analyzing all subjects, multivariable regression analysis demonstrated that headache (P < 0.000) and dizziness (P < 0.000) were most strongly associated with total QOL scores. Conclusions: Based on these data, patients with small-to-medium sized VS enjoy comparable long-term QOL and report high outcome satisfaction whether managed with WSO, MS, or SRS. Strategies addressing dizziness and headache may provide the most impact on QOL improvement for patients with VS.
- 1 October 2006
- Published by CLOCKSS Archive in Molecular Interventions
- Vol. 6 (5) , 249-252
Prospects for an Anti-Ghrelin Vaccine to Treat Obesity
In the battle to treat the pandemic of obesity, one therapeutic strategy is to block endogenous signals that stimulate appetite and control body weight. One such molecule is ghrelin, a gut peptide that is the only known orexigenic hormone and is a likely contributor to mealtime hunger. The relative importance of ghrelin in long-term body-weight regulation (and thus its promise as an anti-obesity target) is uncertain, however, because genetic and pharmacologic blockade of ghrelin signaling have yielded variable results to date. Using a novel approach of vaccinating rats against their own ghrelin, Zorilla et al. report that animals with high ghrelin-specific antibody titers displayed restricted body weight, without evidence of non-specific inflammation following the vaccine. These results favor a meaningful role for ghrelin in energy homeostasis, hinting at a possible new anti-obesity approach. More broadly, the work of Zorilla et al. supports the feasibility of vaccinations directed against specific autologous targets--immunopharmacotherapy that could potentially be developed to target a wide array of medical conditions.
- 1 October 2006
- Published by CLOCKSS Archive in Molecular Interventions
- Vol. 6 (5) , 249-252
Prospects for an Anti-Ghrelin Vaccine to Treat Obesity
In the battle to treat the pandemic of obesity, one therapeutic strategy is to block endogenous signals that stimulate appetite and control body weight. One such molecule is ghrelin, a gut peptide that is the only known orexigenic hormone and is a likely contributor to mealtime hunger. The relative importance of ghrelin in long-term body-weight regulation (and thus its promise as an anti-obesity target) is uncertain, however, because genetic and pharmacologic blockade of ghrelin signaling have yielded variable results to date. Using a novel approach of vaccinating rats against their own ghrelin, Zorilla et al. report that animals with high ghrelin-specific antibody titers displayed restricted body weight, without evidence of non-specific inflammation following the vaccine. These results favor a meaningful role for ghrelin in energy homeostasis, hinting at a possible new anti-obesity approach. More broadly, the work of Zorilla et al. supports the feasibility of vaccinations directed against specific autologous targets--immunopharmacotherapy that could potentially be developed to target a wide array of medical conditions.